Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

About this update from Tarsus Pharmaceuticals, Inc.

IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor. Since joining Tarsus in 2021, Ms. Clase has played an integral role in the Company's evolution from a clinical-stage organization to a successful commercial biopharmaceutical company with one of the best launches in eye care to date. Her leadership has helped shape Tarsus' strategy, advance its strategic priorities and position the Company for sustained long-term growth. Her appointment reflects the depth of experience across the Company's commercial leadership team, as well as its ongoing focus on leadership development and succession planning. The leadership transition comes as Tarsus enters its next phase of growth following the successful commercialization of XDEMVY® and the acquisition of iRenix Medical, Inc., which expands Tarsus' pipeline and further strengthens its position as a leading eye care company. "One of the things I'm most proud of is the caliber of leaders we've been able to attract to Tarsus. Aziz's appointment as CEO of a public medical device company is a reflection of his exceptional leadership and impact, and we're excited to see him take this next step," said Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "Just as importantly, this transition comes at a moment of tremendous momentum for Tarsus. XDEMVY continues to grow, our pipeline is expanding, and we're entering one of the most exciting chapters in our Company's history. Neera has played a pivotal role in building the commercial capabilities that position us for continued success, and she will be supported by an exceptional team of leaders as we continue executing our strategy and delivering for patients." "Being part of the Tarsus team has been one of the greatest privileges of my career," said Mr. Mottiwala. "I'm grateful to Bobby and this entire team for the opportunity to help build one of the strongest commercial organizations in our industry – one that knows how to win, how to lead and, most importantly, puts patients first. I have complete confidence in Neera and the entire commercial leadership team to continue raising the bar and leading Tarsus into its next chapter."

View stock analysis, news, and events for Tarsus Pharmaceuticals, Inc.